SU2C Colorectal Cancer Dream Team: Targeting Genomic, Metabolic and Immunological Vulnerabilities of Colorectal Cancer
Charles S. Fuchs, MD, MPH
Yale Cancer Center
Zhenghe John Wang, PhD
Case Comprehensive Cancer Center
Lewis C. Cantley, PhD
Weill Cornell College of Medicine
Luis A. Diaz Jr., MD
Memorial Sloan Kettering Cancer Center
The Dream Team focuses on three areas of research that have the potential to impact all stages of colorectal cancer. The emphasis of the first two areas of research is on the potential of immunotherapy and targeted therapy to revolutionize the treatment of colorectal cancer, while the last area of study involves strategies to specifically target different colorectal cancer subtypes. In addition, the team seeks to determine the mechanisms of resistance to immunotherapies and targeted therapies, and devise new strategies to overcome the resistance.
FDA approves the use of pembrolizumab in the first-line setting in MSI-H/dMMR colorectal cancer.
Dream Team shows how 5-FU/glutaminase inhibitor CB-389 combination can be efficacious in PIK3CA-mutant colorectal cancer.